Advanced Therapies Integrates 2022 Track 3
MAKING IT
Discover how to manufacture your ATMPs, outsourced or in-house, and the process and analytical technology innovation that underpins success.
Welcome and opening remarks
MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult
Fireside Chat
An interview with:
MARTIN MURPHY | Chief Executive Officer | Syncona Investment Management Limited
Interviewed by:
MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult
Fireside Chat
An interview with:
NICOLA REDFERN | Consultant | NJ Redfern Ltd
Interviewed by:
MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult
Innovate to Elevate
Discover how Process Analytical Technology can improve your ATMP manufacturing and scale up.
FACILITATED BY
Lee Dunham | Head of Collaboration | Cell and Gene Therapy Catapult
PANELLISTS
James Kusena | Vice President of Bioprocessing and Applications | MicrofluidX
Ian Anderson | Global Senior Principal Scientist, Global Biologics | Lonza
Andrea Cusack | CEO and Managing Director | leon-nanodrugs
Steven Binninger | Head of Process Science and Technology | autolomous
Matchmaking
How to find the right partner to outsource your manufacturing and the considerations for setting up a productive partnership.
FACILITATED BY
Jesús Zurdo | Global Head Cell, Gene Therapy & Bioproduction | Horizon Discovery
PANELLISTS
Brian Mullan | Chief Technical Officer | Cell and Gene Therapies, Yposkesi
Michael Baker | Senior Director, Viral Gene Therapy | FUJIFILM Diosynth Biotechnologies
Rui Sousa | Co-founder and CEO | Stemmatters
James Fry | Partner and Head of Life Sciences | Mills & Reeve
ATMP: house blend
Understand when to keep manufacturing in-house and what you need to consider to make that a success e.g. what expertise and skills are required.
FACILITATED BY
Sharon Brownlow | Chief Business Officer | Cell & Gene Therapy Catapult
PANELLISTS
Kasia Averall | Head of Cluster Development | Cell and Gene Therapy Catapult
Angela Osborne | Chief Executive Officer | eXmoor pharma concepts
John Liddell | Chief Technologist | CPI Biologics
David Griffiths-Johnson | Head of Manufacturing | Office for Life Sciences
Oh Industry 4.0
How has Industry 4.0 been adopted and where should the focus be? Our panel discusses digitalisation, sensors and automation, security and sustainability.
FACILITATED BY
Kwok Pang | COO and Co-Founder | Autolomous
PANELLISTS
Nick Stephens | Executive Chairman | The RSA Group
Antoine Espinet | Co Founder & Chief Executive Officer | MicrofluidX
Gaurav Venkataraman | Cofounder and Chief Executive Officer | Trisk Bio
Verity Nancollis | Associate Director, Biologics Development, Manufacturing & Control (BDM&C) | Pharmaron
Andreea Iftimia-Mander | Director of Lifesciences | Biomatics